Search clinical trials for: FF MDI (PT005)

Total 5580 results

Pearl Therapeutics, Inc.

Completed

Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects

Healthy Volunteers

Australia
Pearl Therapeutics, Inc.

Completed

PT003 MDI Dose Confirmation Study

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

COPD, Chronic Obstructive Pulmonary Disease

Belgium
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Chronic Obstructive Pulmonary Disease

United States, Germany, United Kingdom, China, Taiwan, Korea, Republic of, Japan, Czechia, Hungary, Poland, Russian Federation
Pearl Therapeutics, Inc.

Completed

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Chronic Obstructive Pulmonary Disorder

United States, Austria, Belgium, Canada, Denmark, Germany, Italy, Spain, Sweden, United Kingdom, Peru, Brazil, South Africa, Argentina, Russian Federation, Mexico, Puerto Rico, Chile, Norway
Pearl Therapeutics, Inc.

Completed

PT003 MDI Cardiovascular Safety Study

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

COPD

Japan
Pearl Therapeutics, Inc.

Completed

Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD

COPD

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, United States, New Zealand
Pearl Therapeutics, Inc.

Terminated

Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

COPD

United States
Pearl Therapeutics, Inc.

Completed

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (KRONOS)

COPD

United States, Canada, China, Japan
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

COPD

Belgium
AstraZeneca
Parexel

Not yet recruiting

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (ACADIA)

Asthma

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

Asthma

United States
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Active, not recruiting

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Dry Age-related Macular Degeneration

United States, Germany, United Kingdom, France, Spain, Australia, Poland
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PT009001)

Chronic Obstructive Pulmonary Disease

United States
GlaxoSmithKline
Hammersmith Medicines Research

Completed

GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)

Pulmonary Disease, Chronic Obstructive

United Kingdom
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Active, not recruiting

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005 (EXPLORE)

Dry Age-related Macular Degeneration

United States, Germany, United Kingdom, Spain, Poland, Australia, France, Netherlands
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Active, not recruiting

FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD

Eye Diseases | Macular Degeneration | Retinal Degeneration | Geographic Atrophy | Dry Age-related Macular Degeneration | Retinal Disease | Macular Atrophy

United States, United Kingdom
GlaxoSmithKline

Completed

A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)

Asthma

Netherlands
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

United States
Fujifilm Pharmaceuticals U.S.A., Inc.

Completed

Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas

Solid Tumors | Lymphomas

United States
GlaxoSmithKline

Completed

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma (ILA115938)

Asthma

Argentina, Russian Federation, United States, Chile, Thailand
Fujifilm Pharmaceuticals U.S.A., Inc.

Completed

Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

AML, Adult

United States
Guy's and St Thomas' NHS Foundation Trust

Unknown

Fibrillatory Factor in Ventricular Tachycardia

Ventricular Tachycardia

United Kingdom
Pearl Therapeutics, Inc.

Withdrawn

To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease
Fujifilm Pharmaceuticals U.S.A., Inc.

Completed

Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

AML | MDS | CMML

United States
Centre Hospitalier William Morey - Chalon sur Saône
Centre Hospitalier Universitaire Dijon

Recruiting

Dynamic Full-Field Optical Coherence Tomography for Structural and Microbiological Characterization of Central Venous Catheter-deposited Biofilm in Critically Ill Patients (OCT-BIO-CVC)

Critically Ill | Central Venous Catheter Associated Bloodstream Infection | Healthcare Associated Infection

France
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)

Rectal Cancer

United States
Gyroscope Therapeutics Limited
Novartis Pharmaceuticals

Enrolling by invitation

ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study (ORACLE)

Age Related Macular Degeneration (AMD)

United States, Germany, Spain, France, Australia, United Kingdom
University of Colorado, Denver
National Institute on Aging (NIA)

Active, not recruiting

VIdeo Telehealth in ALzheimer's: NeuroPsychology (VITAL-NP) (VITAL-NP)

Suspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)

United States
GlaxoSmithKline

Recruiting

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Asthma

United States
GlaxoSmithKline

Recruiting

Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma

Asthma

China
GlaxoSmithKline

Completed

A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine

Rhinitis, Allergic, Perennial and Seasonal

Australia
GlaxoSmithKline

Completed

Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation

Asthma

Australia
Pearl Therapeutics, Inc.

Completed

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

COPD
GlaxoSmithKline

Completed

Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Romania, Russian Federation, Ukraine, Argentina, Poland, Czechia
GlaxoSmithKline
Parexel

Completed

To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)

Asthma

United States
GlaxoSmithKline

Completed

Randomised Study Comparing the Effects of Inhaled Fluticasone Furoate (FF)/Vilanterol (VI; GW642444M) Combination and FF on an Allergen Induced Asthmatic Response

Asthma

United Kingdom, Germany, New Zealand
Fujifilm Pharmaceuticals U.S.A., Inc.

Recruiting

A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors

Advanced Solid Tumors

United States
GlaxoSmithKline

Completed

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma

Asthma

United States, Argentina, Japan, Poland, Canada, Russian Federation, Spain, Germany, Hungary, South Africa, Italy, Mexico, Romania, Bulgaria, China, Lithuania
Cochlear
Avania

Completed

CP1150 Sound Processor Speech Perception Compared With the Next Generation of Signal Processing Technology

Hearing Impairment, Sensorineural

Australia
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
GlaxoSmithKline

Completed

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Asthma

Australia, United States, Argentina, Canada, Germany, Japan, Korea, Republic of, Romania, Russian Federation, Spain, South Africa, Netherlands, Poland, Italy, United Kingdom
GlaxoSmithKline

Completed

A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function

Asthma

New Zealand
GlaxoSmithKline

Completed

A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Russian Federation, Chile, Poland, Mexico, Estonia, Korea, Republic of, Philippines
Fujifilm Pharmaceuticals U.S.A., Inc.

Recruiting

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors

Advanced Solid Tumors

United States

3

Subscribe